Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 1:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,576 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Retina Disease Clear all
Completed Phase 2Phase 3 Interventional Results available

To Study the Effectiveness and Safety of Niacin and a Topical Steroid Eye Drop to Treat Retinal Vein Occlusions

NCT00493064
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Nicotinic acid, Prednisolone acetate
Drug
Lead sponsor
Palo Alto Medical Foundation
Other
Eligibility
Not listed
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2018 · Synced Oct 28, 2026, 1:38 PM EDT
Not listed Phase 4 Interventional

Assessing the Efficacy and Safety fo DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert(s) for the Treatment of Pain, Inflammation, and Cystoid Macular Edema Following 27 Gauge Vitrectomy With Internal Limiting Membrane Peel for the Treatment of Retinal Edema Associated With Macular Pucker.

NCT04501367
View directory record Official record
Conditions
Vitrectomy, Macular Pucker, Retinal Edema
Interventions
Dexamethasone Intracanalicular Insert, 0.4 mg, Prednisone acetate 1%
Drug
Lead sponsor
Kovach Eye Institute
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Elmhurst, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 28, 2026, 1:38 PM EDT
Completed Phase 4 Interventional

Study of Difluprednate vs. Prednisolone Acetate on Visual Acuity, and Corneal Edema Following Cataract Surgery.

NCT01244334
View directory record Official record
Conditions
Cataracts, Corneal Edema, Retinal Structural Change, Deposit and Degeneration, Visual Acuity Reduced Transiently
Interventions
Difluprednate ophthalmic emulsion 0.05%, Prednisolone acetate 1%
Drug
Lead sponsor
Edward J. Holland
Other
Eligibility
21 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Edgewood, Kentucky • Lynbrook, New York • Mt. Pleasant, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 8, 2012 · Synced Oct 28, 2026, 1:38 PM EDT
Completed Phase 4 Interventional Results available

Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study

NCT01486238
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Macugen® pegaptanib sodium
Drug
Lead sponsor
Valley Retina Institute
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
McAllen, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2013 · Synced Oct 28, 2026, 1:38 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A

NCT00346333
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Lutein, Cornstarch control
Drug · Dietary Supplement
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years to 60 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 31, 2014 · Synced Oct 28, 2026, 1:38 PM EDT
Recruiting Phase 2 Interventional

Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration

NCT07630649
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
Interventions
Ixo-vec
Genetic
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
12
States / cities
Phoenix, Arizona • Bakersfield, California • Fullerton, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 28, 2026, 1:38 PM EDT
Completed No phase listed Observational

Diabetic Retinopathy and Sickle Trait

NCT00720317
View directory record Official record
Conditions
Diabetic Retinopathy, Sickle Cell Trait
Interventions
Not listed
Lead sponsor
Medical University of South Carolina
Other
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 16, 2010 · Synced Oct 28, 2026, 1:38 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD

NCT04331730
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
AKST4290, Placebo, Aflibercept
Drug
Lead sponsor
Alkahest, Inc.
Industry
Eligibility
50 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Beverly Hills, California • St. Petersburg, Florida • Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Oct 28, 2026, 1:38 PM EDT
Not listed Phase 1Phase 2 Interventional

A Study of the NeoVista Ophthalmic System for the Treatment of Subfoveal CNV Associated With Wet AMD in Patients That Require Persistent Anti-VEGF Therapy

NCT00809419
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
NeoVista Ophthalmic System
Device
Lead sponsor
NeoVista
Industry
Eligibility
50 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Phoenix, Arizona • Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jul 27, 2011 · Synced Oct 28, 2026, 1:38 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Alpha Lipoic Acid in Geographic Atrophy

NCT02613572
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
alpha lipoic acid, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
55 Years to 90 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
5
States / cities
Iowa City, Iowa • Teaneck, New Jersey • Eugene, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Oct 28, 2026, 1:38 PM EDT
Active, not recruiting Phase 1 Interventional

Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration

NCT05657301
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
KH631
Drug
Lead sponsor
Chengdu Origen Biotechnology Co., Ltd.
Industry
Eligibility
50 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Phoenix, Arizona • Lemont, Illinois • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 28, 2026, 1:38 PM EDT
Terminated Phase 2 Interventional Results available

Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma

NCT01293539
View directory record Official record
Conditions
Retinoblastoma
Interventions
Melphalan hydrochloride
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
Up to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Oct 28, 2026, 1:38 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention

NCT03859245
View directory record Official record
Conditions
Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), Mid-peripheral Drusen Formation, Diabetic Macular Edema (DME)
Interventions
Photobiomodulation, Ketogenic diet
Behavioral
Lead sponsor
Bristlecone Health, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Eagan, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Oct 28, 2026, 1:38 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina

NCT04976777
View directory record Official record
Conditions
Macular Edema
Interventions
Updated DEX PS DDS Applicator, Approved DEX PS DDS Applicator, Dexamethasone
Device · Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Glendale, California • North Dartmouth, Massachusetts • Independence, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 28, 2026, 1:38 PM EDT
Completed Phase 2Phase 3 Interventional

Neovascular Age Related Macular Degeneration (AMD), Periocular Corticosteroids, and Photodynamic Therapy (PDT)

NCT00305630
View directory record Official record
Conditions
Choroidal Neovascularization, Age-Related Macular Degeneration
Interventions
Periocular injection of triamcinolone acetonide 40mg
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
2
States / cities
Baltimore, Maryland • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 22, 2006 · Synced Oct 28, 2026, 1:38 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD)

NCT00658619
View directory record Official record
Conditions
Macular Degeneration
Interventions
400 µg Brimonidine Tartrate Implant, 200 µg Brimonidine Tartrate Implant, Sham (no implant)
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Abilene, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Oct 28, 2026, 1:38 PM EDT
Completed Phase 3 Interventional Results available

A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)

NCT04480463
View directory record Official record
Conditions
Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
Interventions
SCD411, Aflibercept
Drug
Lead sponsor
Sam Chun Dang Pharm. Co. Ltd.
Industry
Eligibility
50 Years and older
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Campbell, California • Clearwater, Florida • Coral Springs, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 28, 2026, 1:38 PM EDT
Completed Phase 3 Interventional Results available

Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)

NCT00509795
View directory record Official record
Conditions
Macular Degeneration
Interventions
ranibizumab, aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
1,217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
176
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 144 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2012 · Synced Oct 28, 2026, 1:38 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

New Non-invasive Modalities for Assessing Retinal Structure and Function

NCT03475173
View directory record Official record
Conditions
Ischemic Optic Neuropathy, Branch Retinal Artery Occlusion, Hemianopia, Leber Hereditary Optic Neuropathy, Acute Zonal Occult Outer Retinopathy
Interventions
LSFG-NAVI
Device
Lead sponsor
Randy Kardon
Other
Eligibility
18 Years to 99 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 28, 2026, 1:38 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Intraoperative OCT Guidance of Intraocular Surgery II

NCT03713268
View directory record Official record
Conditions
Macular Holes, Epiretinal Membrane, Diabetic Retinopathy, Retinal Detachment, Retinal Disease, Preretinal Fibrosis, Cataract, Ocular Tumor, Strabismus, Healthy
Interventions
Microscope integrated optical coherence tomography
Device
Lead sponsor
Duke University
Other
Eligibility
4 Weeks and older
Enrollment
262 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 28, 2026, 1:38 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

A Snapshot Adaptive Optics and Hyperspectral Autofluorescence Fundus Camera for Age-Related Macular Degeneration (AMD)

NCT03963817
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
adaptive optics AO-OCT/AF instrument
Diagnostic Test
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
60 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 28, 2026, 1:38 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of BIIB111 for the Treatment of Choroideremia

NCT03496012
View directory record Official record
Conditions
Choroideremia
Interventions
BIIB111
Genetic
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older · Male only
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
8
States / cities
Los Angeles, California • Miami, Florida • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Oct 28, 2026, 1:38 PM EDT
Completed No phase listed Observational

Evaluation of OCT Measurements

NCT01806402
View directory record Official record
Conditions
Assess Eye Measurements in Patients Having Retina Pathology or Glaucoma
Interventions
Not listed
Lead sponsor
Optovue
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
3
States / cities
Daly City, California • Petaluma, California • Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2014 · Synced Oct 28, 2026, 1:38 PM EDT
Completed Phase 1 Interventional

A Study of Foscarnet Plus Ganciclovir in the Treatment of Cytomegalovirus of the Eye in Patients With AIDS Who Have Already Been Treated With Ganciclovir

NCT00000970
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Foscarnet sodium, Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 28, 2026, 1:38 PM EDT